Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 488 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizo-Affective Disorder Clear all
Completed Phase 1 Interventional

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

NCT01592110
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
Drug · Other
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Early Phase 1 Interventional

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

NCT01519557
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DAR-100A, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis

NCT03390491
View directory record Official record
Conditions
Psychosis, Schizoaffective Disorder, Schizophrenia
Interventions
OnTrack>TheGame (OTG), Recovery Videos (RV)
Behavioral
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
16 Years to 30 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Not applicable Interventional

Understanding How Cognitive Remediation Works

NCT01683539
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression, Bipolar Disorder
Interventions
The Thinking Skills for Work Program, The Cognitive Skills for Work Program
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 11, 2026, 1:25 PM EDT
Withdrawn Not applicable Interventional

Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)

NCT04068857
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
rTMS
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode

NCT02267070
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Case management and supportive psychotherapy, Family psychoeducation, Cognitive training, Aerobic exercise
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 4 Interventional Results available

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

NCT00535145
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
Interventions
Treatment as usual (TAU), Paliperidone ER
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
21
States / cities
Cerritos, California • Chino, California • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 2Phase 3 Interventional

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

NCT00395031
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

NCT00641745
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl, Risperidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 11, 2026, 1:25 PM EDT
Completed No phase listed Observational

Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors

NCT02224430
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
schizophrenia/schizoaffective disorder.
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness

NCT03062267
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Mobile Interventionist
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 1 Interventional

Digoxin Drug-Drug Interaction With Lurasidone HCl

NCT01082289
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia

NCT01339858
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
Interventions
N-Acetyl Cysteine, sugar pill
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Not applicable Interventional

Financial Incentives to Improve Medication Adherence

NCT04191876
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
Interventions
Wellth - Financial Incentives
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Not applicable Interventional

Cognitive Training and Enhanced Supported Employment in Schizophrenia

NCT00339170
View directory record Official record
Conditions
Schizophrenia
Interventions
Computer-Based Cognitive Enhancement Training Program, Work Therapy Program
Behavioral
Lead sponsor
Yale University
Other
Eligibility
20 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 11, 2026, 1:25 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Psychiatric Genotype/Phenotype Project Repository

NCT00762866
View directory record Official record
Conditions
Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 1 Interventional

Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness

NCT00500695
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivational Interviewing, Psychoeducation
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 11, 2026, 1:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glutamate, Brain Connectivity and Duration of Untreated Psychosis

NCT02034253
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder
Interventions
Risperidone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
17 Years to 35 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Results available

Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia

NCT04414930
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
d-amphetamine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

NCT00588731
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 4 Interventional Results available

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

NCT00373672
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
armodafinil (Nuvigil), placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

NCT00802100
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Perphenazine, Aripiprazole, Metformin, Simvastatin, Benztropine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 11, 2026, 1:25 PM EDT
Completed Not applicable Interventional

A Study of Strategies to Improve Schizophrenia Treatment

NCT00156637
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Team-Based Quality Improvement Intervention, Opinion Leader Intervention, Team Based Quality Improvement
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Fayetteville, Arkansas • No. Little Rock, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 11, 2026, 1:25 PM EDT
Recruiting Phase 4 Interventional

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

NCT03495024
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Interventions
Varenicline
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 11, 2026, 1:25 PM EDT